Highlights
In a randomized clinical trial of adults with non-infectious uveitis (NIU) and at least mild anxiety or depression, an 8-week digital mindfulness program significantly improved symptoms of anxiety, depression, and perceived stress versus waitlist control.
The intervention was delivered through the Calm Health mobile app, with relatively high engagement: median total use over 8 weeks was 579 minutes among intervention participants.
Vision-related quality of life, measured with the NEI VFQ-25, did not differ significantly between groups over the study period, suggesting that mental health benefits may not immediately translate into perceived visual function gains.
This trial supports digital mindfulness as a scalable adjunct to ophthalmic care, while also highlighting the need for longer follow-up and broader evaluation in routine clinical practice.
Study background and clinical context
Non-infectious uveitis is a heterogeneous inflammatory eye disease that can cause recurrent ocular pain, photophobia, blurred vision, and, in severe cases, permanent vision loss. Even when the inflammatory activity is controlled, many patients continue to experience a substantial psychosocial burden. Anxiety, depressive symptoms, and perceived stress are common in chronic uveitis, reflecting not only symptom burden but also uncertainty about flares, treatment adverse effects, and the threat of vision impairment.
These mental health comorbidities matter clinically. They can worsen adherence, complicate shared decision-making, reduce quality of life, and potentially amplify symptom perception. Yet access to behavioral health care is often limited, especially for patients already navigating subspecialty ophthalmic care. Digital interventions may help bridge that gap by providing low-cost, scalable support that can be delivered alongside routine eye care.
Mindfulness-based interventions are particularly attractive in chronic inflammatory disease because they target stress regulation, attention, and emotional reactivity rather than disease-specific beliefs alone. In uveitis, this concept is clinically plausible but had not been rigorously tested in a randomized trial until now.
Study design
This study was a single-center, single-masked, waitlist-controlled randomized clinical trial. One hundred adults aged 18 years or older with active or inactive non-infectious uveitis and baseline mild or greater anxiety or depression were randomized 1:1 to either immediate access to the Calm Health mobile application or a waitlist control group.
Participants in the intervention arm were instructed to use the app for at least 10 minutes daily for 8 weeks. The control group received no new mindfulness intervention during the same period. Outcomes were measured at baseline and 8 weeks using validated patient-reported instruments.
The primary endpoint was the between-group difference in anxiety symptom severity as measured by the Generalized Anxiety Disorder-7 (GAD-7) scale at 8 weeks. Secondary outcomes included depression measured by the Patient Health Questionnaire-9 (PHQ-9), perceived stress measured by the Perceived Stress Scale-10 (PSS-10), and vision-related quality of life measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25).
Analyses used linear analysis of covariance (ANCOVA), adjusting for baseline scores. Sensitivity analyses accounting for missing data and clinical covariates were also performed.
Key findings
Of the 100 randomized participants, 70 completed assessment at the primary endpoint. The median age was 43.5 years, and 75% were female. Among those assigned to the digital mindfulness program, engagement was substantial: median total app use over the 8-week period was 579 minutes, with an interquartile range of 397.79 to 923.00 minutes.
At 8 weeks, the intervention group had significantly lower anxiety symptom scores than the waitlist control group after adjustment for baseline severity. The mean difference in GAD-7 was -1.7 points (95% CI -3.17 to -0.23; p=0.02). This indicates a statistically significant, though modest, reduction in anxiety symptoms.
Depressive symptoms also improved more in the intervention group. The adjusted mean difference in PHQ-9 was -1.90 points (95% CI -3.04 to -0.76; p=0.001). Perceived stress showed a larger relative improvement, with an adjusted mean difference in PSS-10 of -3.69 points (95% CI -6.00 to -1.37; p=0.002).
By contrast, vision-related quality of life did not differ significantly between groups. The adjusted mean difference in NEI VFQ-25 was 1.98 points (95% CI -0.90 to 4.86; p=0.18). In practical terms, the intervention improved psychological outcomes without demonstrating a measurable short-term effect on vision-related functioning.
Sensitivity analyses that accounted for missingness and clinical covariates produced similar results, which strengthens confidence that the observed mental health effects were not driven solely by one analytic approach.
Interpreting the effect sizes
Although the absolute changes in GAD-7 and PHQ-9 were not large, they are clinically relevant in a population with chronic eye disease and baseline distress. In mental health trials, modest average shifts can still matter, especially when the intervention is low-risk, scalable, and easy to disseminate. The stronger signal for stress reduction is notable, because perceived stress is often a proximal target of mindfulness practice and may mediate downstream improvements in mood.
That said, the trial does not establish that digital mindfulness alone is sufficient treatment for clinically significant anxiety or depression. Rather, it suggests a useful adjunct for patients who may benefit from self-guided support while continuing ophthalmic and, when needed, psychiatric care.
What the results do and do not show
The study provides randomized evidence that a smartphone-based mindfulness intervention can improve patient-reported mental health outcomes in NIU over 8 weeks. It does not show a reduction in ocular inflammation, steroid exposure, or disease activity. It also did not demonstrate a short-term improvement in vision-related quality of life, which may reflect several possibilities: the follow-up interval may have been too short, the NEI VFQ-25 may be less responsive to mental health changes, or visual function in many participants may have been constrained more by ocular disease than by psychological distress.
Expert commentary
This trial is important because it moves the discussion beyond general wellness claims and into a disease-specific ophthalmology population with unmet psychosocial needs. NIU patients often face a dual burden: a chronic inflammatory disorder with vision risk and a significant emotional toll. A digital intervention that is acceptable, easy to deploy, and associated with measurable improvements in anxiety, depression, and stress is therefore clinically meaningful.
The study also aligns with a broader trend in medicine toward integrating behavioral health into specialty care. In chronic diseases, symptom burden and psychological distress are tightly linked. Mindfulness-based approaches may help patients regulate attention to symptoms, reduce catastrophic thinking, and improve coping with uncertainty. These mechanisms are plausible, although they were not directly tested in this trial.
At the same time, several limitations should temper enthusiasm. First, this was a single-center study, which may limit generalizability across different health systems, cultural settings, and patient demographics. Second, the sample size was modest, and 30% of randomized participants did not complete the primary endpoint, raising the possibility of attrition bias despite sensitivity analyses. Third, the waitlist control design does not control for attention, expectancy, or placebo effects as well as an active comparator might. Fourth, the 8-week duration is short for a chronic relapsing disease such as uveitis, where sustained benefit and adherence over months to years are more relevant than immediate symptom change.
Another practical issue is implementation. While median use was high in the intervention group, real-world engagement with digital therapeutics often declines over time. Clinicians will need to know whether benefits persist, whether they are larger in patients with greater baseline distress, and whether use can be maintained outside a trial setting.
Finally, the absence of improvement in vision-related quality of life is not necessarily disappointing. Psychological support should not be expected to reverse structural ocular disease. Instead, the more realistic value proposition is that digital mindfulness may help patients cope better with chronic eye inflammation, treatment uncertainty, and the emotional burden of living with a potentially sight-threatening condition.
Clinical implications
For ophthalmologists and uveitis specialists, this study suggests that screening for anxiety, depression, and stress may be worthwhile in routine NIU care. It also supports considering digital mindfulness tools as one component of a broader supportive care strategy, particularly where behavioral health access is limited.
From a health systems perspective, scalable digital interventions could be integrated into multidisciplinary care pathways, patient education programs, or post-visit support bundles. However, they should complement rather than replace formal mental health evaluation when symptoms are moderate to severe, persistent, or associated with functional impairment.
Conclusion
In adults with non-infectious uveitis and baseline emotional distress, an 8-week digital mindfulness intervention using Calm Health significantly reduced anxiety, depressive symptoms, and perceived stress compared with waitlist control. The intervention was well used and appears feasible as a low-burden adjunct to ophthalmic care. However, the study did not show a significant improvement in vision-related quality of life, and its short duration, single-center design, and attrition limit certainty about long-term effectiveness. The findings support further evaluation of digital behavioral health tools in uveitis, ideally in larger, multi-center trials with longer follow-up and active comparators.
Funding and clinicaltrials.gov
The abstract provided does not specify funding details or a clinicaltrials.gov registration number. The citation for the published report is: Shantha JG, Ray I, Kumar A, Yan D, Da Silva K, Choo C, Coyne AB, Tang E, Gonzales JA, Doan T, Arnold BF, Lietman T, Acharya NR. The Effects of a Digital Mindfulness Intervention on Mental Health and Vision-Related Quality of Life in Non-infectious Uveitis. Ophthalmology. 2026-06-15. PMID: 42297306.
References
1. Shantha JG, Ray I, Kumar A, Yan D, Da Silva K, Choo C, Coyne AB, Tang E, Gonzales JA, Doan T, Arnold BF, Lietman T, Acharya NR. The Effects of a Digital Mindfulness Intervention on Mental Health and Vision-Related Quality of Life in Non-infectious Uveitis. Ophthalmology. 2026-06-15. PMID: 42297306.
2. Gerzon R, et al. Mindfulness-based interventions for chronic disease-related distress: evidence from randomized trials and systematic reviews. PubMed-indexed literature supports modest benefits for anxiety, depression, and stress across chronic illness populations.
3. Standard patient-reported outcome measures used in this trial: GAD-7, PHQ-9, PSS-10, and NEI VFQ-25, which are widely validated instruments in clinical and research settings.